Jim Cramer Wants A Bitcoin ETF, But Doesn't Like A Company That Owns 'A Lot Of Cryptocurrencies'

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Origin Materials, Inc. ORGN doesn’t make any money. "As soon as it starts making money, we can start looking at these companies that are good for the environment," he added.

Cramer said he is worried about Orange S.A. ORAN. He added, "I see that 7% yield and I say to myself, wow, that’s up there with the Verizon’s VZ, which I’m always worried about. However, I like your idea longer term. I think it’s very good because they are one of the only games in town."

When asked about The Walt Disney Company DIS, he said, "I think this quarter’s going to be a very tough quarter. And the movies weren’t that good. I think the next quarter is going to be very tough too. I think it’s going to take a year."

Don’t forget to check out our premarket coverage here

The "Mad Money" host said Ferrari N.V. RACE is a "true juggernaut," adding that it has "defied me, because I always felt that on basis of price to earnings it was too high. But they know what they’re doing, they’re in charge, the stock’s been great since it became public, and it’s winning over converts like me."

When asked about Marathon Digital Holdings, Inc. MARA, he said, "I want an ETF for Bitcoin BTC/USD or I want to own Bitcoin. I don’t want to own just companies that like own a lot of cryptocurrencies, because they can’t find out what they own. Not knocking them, just saying they can’t find out enough."

Cramer said The Kraft Heinz Company KHC has some of the worst brands he has ever seen. "They are the bad brand company," he added.

Price Action: Shares of Kraft Heinz fell 0.5% to close at $35.66, while Marathon Digital dropped 1.5% to $15.32 on Thursday. Ferrari shares fell 2% to $313.53, while Disney shares dropped 1.2% to settle at $88.74 during the same session. Origin Materials shares dropped 9.9% to $3.75, while Orange shares slipped 1.1% to settle at $11.32 on Thursday.

Now Read This: $40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying